Boris Peaker analyst TD COWEN

Currently out of the existing stock ratings of Boris Peaker, 23 are a HOLD (38.33%), 37 are a BUY (61.67%).

Boris Peaker

Work Performance Price Targets & Ratings Chart

Analyst Boris Peaker, currently employed at TD COWEN, has had 66.85% of price targets met with an average potential upside of 29.33%, reached in 136 days on average. Previously, Boris Peaker worked at OPPENHEIMER.

Boris Peaker has documented 117 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IRWD, Ironwood Pharmaceuticals at 12-Jan-2024.

Wall Street Analyst Boris Peaker

Analyst best performing recommendations are on SGEN (SEAGEN).
The best stock recommendation documented was for HRTX (HERON THERAPEUTI) on 11/15/2023. The price target of $2.5 was fulfilled within 70 days with a profit of $1.64 (190.7%), with a performance score of 27.24.

Average potential price target upside

CLDX Celldex Therapeutics EBS Emergent Biosolutions HRTX Heron Therapeuti SGEN Seagen IRWD Ironwood Pharmaceuticals MRK Merck mpany CTIC CTi Biopharma Corp PCRX Pacira Pharmaceuticals INCY yte LNTH

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 08-May-2026

$50

$22.04 (78.83%)

$53

2 days ago
(20-Nov-2026)

Buy Since 03-Jun-2014

$58

$30.04 (107.44%)

$64

2 days ago
(20-Nov-2026)

Buy Since 20-Mar-2025

$61

$33.04 (118.17%)

$57

13 days ago
(09-Nov-2026)

2/7 (28.57%)

$29.76 (95.26%)

237

Buy Since 28-Apr-2025

$68

$40.04 (143.20%)

$60

13 days ago
(09-Nov-2026)

0/6 (0%)

$36.76 (117.67%)

Buy Since 10-Sep-2021

$88

$60.04 (214.74%)

$78

1 months 30 days ago
(23-Sep-2026)

0/4 (0%)

$56.88 (182.78%)

Show more analysts

Stocks Boris Peaker covered previously. Scores are shown for active stocks only.

AADI Aadi Bioscience ADCT CELC Celcuity LLC CTMX CytomX Therapeutics JNCE Jounce Therapeutics PNT POINT Biopharma Global

Please expand the browser size to see the chart

What Year was the first public recommendation made by Boris Peaker?

On 2011
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?